Daniel A Tatosian Selected Research

2- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amine

12/2019	Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
9/2016	A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
1/2016	Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel A Tatosian Research Topics

Disease

6	Type 2 Diabetes Mellitus (MODY) 12/2019 - 12/2013
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2019
1	Body Weight (Weight, Body) 01/2017
1	Obesity 01/2016
1	Neoplasms (Cancer) 05/2009

Drug/Important Bio-Agent (IBA)

3	2- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amineIBA 12/2019 - 01/2016
2	Sitagliptin Phosphate (Januvia)FDA Link 01/2019 - 12/2013
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	saxagliptin FDA Link 12/2013
1	VildagliptinIBA 12/2013
1	Pharmaceutical PreparationsIBA 05/2009

Therapy/Procedure

1	Therapeutics 01/2018